Raymond James Financial Inc. Takes $2.50 Million Position in GoodRx Holdings, Inc. (NASDAQ:GDRX)

Raymond James Financial Inc. acquired a new position in shares of GoodRx Holdings, Inc. (NASDAQ:GDRX - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 537,530 shares of the company's stock, valued at approximately $2,500,000. Raymond James Financial Inc. owned about 0.14% of GoodRx at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in GDRX. Versor Investments LP acquired a new stake in GoodRx during the 4th quarter valued at approximately $54,000. Verus Capital Partners LLC bought a new stake in shares of GoodRx in the 4th quarter valued at $55,000. Steward Partners Investment Advisory LLC acquired a new stake in shares of GoodRx during the fourth quarter worth $56,000. Aigen Investment Management LP bought a new position in GoodRx during the fourth quarter worth $62,000. Finally, EP Wealth Advisors LLC acquired a new position in GoodRx in the third quarter valued at $73,000. 63.77% of the stock is owned by institutional investors and hedge funds.

GoodRx Stock Up 3.2 %

GDRX stock traded up $0.14 during midday trading on Wednesday, reaching $4.57. 1,470,460 shares of the company's stock traded hands, compared to its average volume of 1,366,614. The company has a quick ratio of 5.48, a current ratio of 5.48 and a debt-to-equity ratio of 0.70. The firm's fifty day moving average price is $4.75 and its 200-day moving average price is $5.23. GoodRx Holdings, Inc. has a 52 week low of $4.09 and a 52 week high of $9.26. The company has a market cap of $1.75 billion, a price-to-earnings ratio of -152.33, a P/E/G ratio of 2.46 and a beta of 1.25.

Remove Ads

Wall Street Analyst Weigh In

GDRX has been the subject of several research analyst reports. Wells Fargo & Company lowered their price objective on GoodRx from $9.00 to $8.00 and set an "overweight" rating for the company in a research report on Friday, February 28th. Citigroup dropped their price target on GoodRx from $7.00 to $6.25 and set a "buy" rating on the stock in a research note on Friday, January 10th. Morgan Stanley reduced their price objective on shares of GoodRx from $7.00 to $6.00 and set an "equal weight" rating for the company in a research report on Tuesday, December 17th. Mizuho assumed coverage on shares of GoodRx in a research note on Wednesday, December 4th. They issued a "neutral" rating and a $5.00 price objective for the company. Finally, KeyCorp reduced their price target on shares of GoodRx from $7.00 to $6.00 and set an "overweight" rating for the company in a report on Wednesday, January 8th. Three research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $8.18.

GoodRx Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.